Sarcoma Drug Market Increasing Demand, Growth Analysis and Future Outlook by 2031

Global sarcoma drug market is anticipated to grow at a CAGR of 8.3% during the forecast period (2024-2031). The rising FDA approvals for sarcoma drugs are a key factor driving the growth of the global sarcoma drugs market. For instance, in May 2022, Washington University School of Medicine developed an investigational drug to attack synovial sarcoma, a rare soft tissue tumor. The drug triggers cell death and is set for a phase 1 clinical trial to assess its safety and effectiveness in patients with sarcomas that have spread beyond the original tumor site.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/sarcoma-drug-market

Further, in November 2021, Aadi Bioscience's Fyarro, its first commercial product, was approved by the FDA for adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors. The FDA approved Fyarro based on data from a phase 2 registrational trial, with 29.9% of patients achieving an overall response.

Furthermore, in February 2020, Epizyme's Tazverik, a first-in-class EZH2 inhibitor, was approved for treating epithelioid sarcoma (ES), a rare soft tissue tumor. The drug, which is expected to gain market value through wider use in more lucrative cancer settings, is expected to be available in the US for approximately 300 patients.

Global Sarcoma Drug Market Report Segment

By Treatment Type

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Others (Radiation Therapy)

By Disease Indication

• Soft Tissue Sarcoma (STS)
• Bone Sarcoma
• Gastrointestinal Stromal Tumors (GIST)
• Kaposi Sarcoma

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

A full report of Sarcoma Drug Market available @ https://www.omrglobal.com/industry-reports/sarcoma-drug-market

Sarcoma Drug Market Report Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• AbbVie Inc.
• Adaptimmune Ltd.
• Arcus Biosciences, Inc.
• AstraZeneca Plc
• Bristol Myers Squibb Co.
• Eisai Co., Ltd.
• F. Hoffmann-La Roche Ltd.
• Fresenius Kabi AG
• Gilead Sciences, Inc.
• GlaxoSmithKline plc.

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.


Visit more report at

https://www.linkedin.com/pulse/scaffold-technology-market-size-trends-latest-arti-vishwakarma-mlsof/

https://www.linkedin.com/pulse/aesthetic-threads-market-increasing-demand-growth-2031-vishwakarma-pyg5f

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.